Kedrion’s CEO, newly elected chairman of PPTA, opens the PPTA Plasma Protein Forum
Paolo Marcucci, President and CEO of Kedrion and newly elected Chairman of the Plasma Protein Therapeutics Association (PPTA), opened the PPTA Plasma Protein Forum 2013. This is one of the most important events that the world association of manufacturers of plasma-derived medicinal products organises every year to present the main challenges that the industry is
Kedrion presents the new Factor VIII for the Hungarian market
Today, at the Hungarian Academy of Sciences in Budapest, a scientific symposium celebrated the launch on the Hungarian market of the new plasma-derived product Factor VIII by Human BioPlazma, Kedrion Group’s Budapest-based subsidiary, which runs the production plant of Gödöllő. Manufactured at the production plant of Bolognana through the purification of an intermediate product received
Haemopilia, Kedrion supports the workshop on the efficiency of the blood system
Vicenza hosted the workshop “The Blood System in Italy: Criticalities and Resources in the Treatment of Haemophilia”, organised by professor Francesco Rodegherio, Director of Cellular Therapies and Haematology at Ospedale San Bortolo of Vicenza, with Kedrion’s educational support. The workshop was attended by clinicians (Haemophilia Centres, Regional Blood Centres, Transfusion Centres, National Blood Centre), pharmacists,
Grifols trnasfers to Kedrion the management of the plasma fractionation plant of Melville (USA), owned by Kedrion
Kedrion announces that, effective 1st July, 2013, Grifols S.A. will complete the transfer to Kedrion of all the operations for managing the plasma fractionation plant of Melville, State of New York (USA), owned by Kedrion. This action is part of the agreements entered into in 2011, included in the Consent Agreement of the Federal Trade
Kedrion supports initiatives for World Haemophilia Day. Partner in a project for export of blood-derived products from national plasma for humanitarian purposes
Kedrion confirms its support of the World Haemophilia Day, an initiative that is now in its 9th year in Italy and is usually celebrated on 17th April, aimed to raise awareness of haemophilia and similar conditions. The slogan chosen by the World Federation of Haemophilia (WFH) for 2013, again, is “Close the Gap”, a catchphrase
Agreement with Entegrion for the development and marketing of Resusix™, a virus inactivated spray-dried plasma
Kedrion Melville Inc., a US-based company owned by Kedrion, entered into an agreement with the US-based company Entegrion Inc. for the development and marketing of Resusix™, a virus inactivated spray-dried plasma, treated with solvent-detergent, to be used as a replacement of frozen fresh plasma. The Phase-I clinical trials that have recently been authorised by the
The Jeffrey Modell Foundation visits Kedrion
Today, Vicki and Fred Modell, founders of the Jeffrey Modell Foundation, met Kedrion’s management in the company’s headquarters in Castelvecchio Pascoli. JMF is an international non-profit organisation founded in 1987 in memory of their son Jeffrey who died at the age of 15 from complications of Primary Immunodeficiency (PI), and works to help patients affected
Kedrion supports Italy’s first Jeffrey Modell Paediatric Immunology Centre
With a three-year donation, Kedrion supported the creation of the first Jeffrey Modell Paediatric Immunology Centre in Italy. As a matter of fact, from now on the Paediatric Immunology Centre of Meyer University Hospital in Florence will be part of the Jeffrey Modell Centres network for the diagnosis, treatment and research of Primitive Immune Deficiencies
First official visit of the Regional Health Councillor for Tuscany, Luigi Marroni
Yesterday, the Regional Health Councillor for Tuscany, Luigi Marroni visited Kedrion, an Italian leading biopharmaceutical company and also one of the top worldwide companies in the development, production and distribution of plasma-derived products. The Councillor, who was on his first official visit, met Paolo Marcucci, Kedrion’s President and CEO. Hon. Marroni visited Kedrion Group’s main
Kedrion reinforces its presence in the United States. Agreement with US-bades OCD for the acquisition of one of the company’s branches
Kedrion reinforces its presence in the United States. The company, based in Castelvecchio Pascoli (Lucca), acquired from Ortho-Clinical Diagnostics, Inc. (OCD) the branch specialising in the production of human anti-D immunoglobulin, an effective product for the prevention of the “haemolytic disease of the newborn” (HDN), a condition that occurs in Rh-positive foetuses and new-born babies